BioCentury
ARTICLE | Company News

Zealand and Orbit in peptide discovery deal

November 3, 2017 7:32 PM UTC

In September, gastrointestinal and metabolic disease company Zealand Pharma A/S (CSE:ZEAL; NASDAQ:ZEAL) and Orbit Discovery (Oxford, U.K.) partnered to discover and develop peptides against multiple targets. Orbit will screen its peptide libraries against undisclosed targets selected by Zealand. Zealand will be responsible for optimization...

BCIQ Company Profiles

Zealand Pharma A/S